<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277470</url>
  </required_header>
  <id_info>
    <org_study_id>NL48785.018.14</org_study_id>
    <nct_id>NCT02277470</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis</brief_title>
  <acronym>GO-KINETIC</acronym>
  <official_title>Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain insights in the pharmacokinetics of golimumab in
      moderate to severe Ulcerative Colitis after subcutaneous administration, during induction and
      maintenance treatment the investigators will collect blood and stool samples at different
      time points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetic characteristics of golimumab will be assessed by using blood and stool
      samples; collected during induction and maintenance treatment Patients will undergo 13-16
      blood sample collections, 13-16 stool sample collections and 3 endoscopies during 16 hospital
      visits in 1 year. They are also asked to fill in a short questionnaire (9x). At endoscopy
      visits a questionnaire regarding quality of life will be taken.The population
      pharmacokinetics of golimumab will be assessed using nonlinear mixed-effects modelling
      (NON-MEM).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Golimumab concentrations (peak/trough,AUC)</measure>
    <time_frame>day 0,1,4,7,14,18, week 4,6,10,18,30,42,52</time_frame>
    <description>By measuring golimumab concentrations at different time point during induction and maintenance therapy we can determine pharmacokinetic parameters of golimumab in ulcerative colitis patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of Golimumab-antibodies</measure>
    <time_frame>day 0,1,4,7,14,18, week 4,6,10,18,30,42,52</time_frame>
    <description>Assessment of neutralizing antidrug-antibodies by radiomimmuno assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic response</measure>
    <time_frame>week 10, 52</time_frame>
    <description>defined by improvement in endoscopic Mayo score of at least 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response by SCCAI</measure>
    <time_frame>week 10, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life by IBDQ, SF-36</measure>
    <time_frame>week 10, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal calprotectin</measure>
    <time_frame>day 0,1,4,7,14,18, week 4,6,10,18,30,42,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal golimumab levels</measure>
    <time_frame>day 1,4,7,14,18, week 4,6,8,18,30,42,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum CRP</measure>
    <time_frame>day 0,1,4,7,14,18, week 4,6,10,18,30,42,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>day 1,4,7,14,18, week 4,6,10,18,30,42,52</time_frame>
    <description>calculated from primary outcome (concentrations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Albumin</measure>
    <time_frame>day 0,1,4,7,14,18, week 4,6,10,18,30,42,52</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Golimumab</arm_group_label>
    <description>Patients who are eligible for golimumab therapy.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples and blood samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for inclusion are patients (either outpatient or hospitalized) with
        moderate to severe UC refractory to corticosteroids and immunomodulators.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 years, either male or female

          -  Moderate to severe UC (according to Mayo score (2 or 3) baseline endoscopy), both
             anti-TNF na√Øve and anti-TNF exposed patients will be included

          -  Baseline endoscopy

          -  Obtained written informed consent

        Exclusion Criteria:

          -  Contra-indication to golimumab: TBC, severe infections or congestive heart failure.

          -  Imminent need for surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert R D'Haens, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mark lowenberg, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron Mathot, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pleun S. van Egmond, MSc</last_name>
    <phone>0205663874</phone>
    <email>p.s.vanegmond@amc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanke Brandse, drs</last_name>
    <phone>0205667805</phone>
    <email>j.f.brandse@amc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1091AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pleun S. van Egmond, MSc</last_name>
      <phone>020-5663874</phone>
      <email>p.s.vanegmond@amc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Toos Schakel</last_name>
      <phone>020-5992214</phone>
      <email>T.G.Schakel-vandenBerge@olvg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jeroen Jansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pleun S. van Egmond, MSc</last_name>
      <phone>020-5663874</phone>
      <email>p.s.vanegmond@amc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Hanke Brandse, Drs</last_name>
      <phone>020-5667850</phone>
      <email>j.f.brandse@amc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Hanke Brandse</investigator_full_name>
    <investigator_title>drs.</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics, Golimumab, IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

